drugset
drugset / Trial / NCT00747058

A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects

NCT00747058 ↗

Phase 1 Completed 28 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and tolerability of PF-03864086 in healthy male human volunteers. Determine the pharmacokinetics (calculations of the rate of elimination of PF-03864086 from the body once the compound is ingested).

Timeline

Start
2008-08
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-3864086 Unknown 3 mg Oral
Subject PF-3864086 Unknown 10 mg Oral
Subject PF-3864086 Unknown 30 mg Oral
Subject PF-3864086 Unknown 60 mg Oral
Subject PF-3864086 Unknown 120 mg Oral
Subject PF-3864086 Unknown 240 mg Oral
Subject PF-3864086 Unknown 480 mg Oral
Subject PF-3864086 Unknown 720 mg Oral

Indications

No indication recorded.